209 related articles for article (PubMed ID: 11482696)
1. Clinical features and medical treatment of male prolactinomas.
Asano S; Ueki K; Suzuki I; Kirino T
Acta Neurochir (Wien); 2001; 143(5):465-70. PubMed ID: 11482696
[TBL] [Abstract][Full Text] [Related]
2. [Results of treatment for male prolactinomas].
Iwai Y; Yamanaka K; Ishiguro T; Morikawa T; Matsuzaka Y; Komiyama M; Yasui T
No Shinkei Geka; 2002 Dec; 30(12):1285-92. PubMed ID: 12491580
[TBL] [Abstract][Full Text] [Related]
3. Diagnosis and drug therapy of prolactinoma.
Ciccarelli E; Camanni F
Drugs; 1996 Jun; 51(6):954-65. PubMed ID: 8736617
[TBL] [Abstract][Full Text] [Related]
4. Effects of bromocriptine and terguride on cell proliferation and apoptosis in the estrogen-stimulated anterior pituitary gland of the rat.
Yonezawa K; Tamaki N; Kokunai T
Neurol Med Chir (Tokyo); 1997 Dec; 37(12):901-6. PubMed ID: 9465588
[TBL] [Abstract][Full Text] [Related]
5. Combined treatment of invasive giant prolactinomas.
Yu C; Wu Z; Gong J
Pituitary; 2005; 8(1):61-5. PubMed ID: 16411070
[TBL] [Abstract][Full Text] [Related]
6. Cost-Effectiveness Analysis of Microscopic and Endoscopic Transsphenoidal Surgery Versus Medical Therapy in the Management of Microprolactinoma in the United States.
Jethwa PR; Patel TD; Hajart AF; Eloy JA; Couldwell WT; Liu JK
World Neurosurg; 2016 Mar; 87():65-76. PubMed ID: 26548828
[TBL] [Abstract][Full Text] [Related]
7. 10-year follow-up study comparing primary medical vs. surgical therapy in women with prolactinomas.
Andereggen L; Frey J; Andres RH; El-Koussy M; Beck J; Seiler RW; Christ E
Endocrine; 2017 Jan; 55(1):223-230. PubMed ID: 27688009
[TBL] [Abstract][Full Text] [Related]
8. [Prolactinoma; diagnosis and treatment].
van der Lely AJ; de Herder WW; Hofland LJ; Lamberts SW
Ned Tijdschr Geneeskd; 1996 Jul; 140(28):1445-9. PubMed ID: 8766768
[No Abstract] [Full Text] [Related]
9. Update on prolactinomas. Part 2: Treatment and management strategies.
Wong A; Eloy JA; Couldwell WT; Liu JK
J Clin Neurosci; 2015 Oct; 22(10):1568-74. PubMed ID: 26243714
[TBL] [Abstract][Full Text] [Related]
10. Giant prolactinomas: clinical management and long-term follow up.
Shrivastava RK; Arginteanu MS; King WA; Post KD
J Neurosurg; 2002 Aug; 97(2):299-306. PubMed ID: 12186457
[TBL] [Abstract][Full Text] [Related]
11. Clinical and histological correlations in prolactinomas, with special reference to bromocriptine resistance.
Delgrange E; Sassolas G; Perrin G; Jan M; Trouillas J
Acta Neurochir (Wien); 2005 Jul; 147(7):751-7; discussion 757-8. PubMed ID: 15971099
[TBL] [Abstract][Full Text] [Related]
12. Diagnosis and treatment of prolactinomas.
Molitch ME
Adv Intern Med; 1999; 44():117-53. PubMed ID: 9929707
[No Abstract] [Full Text] [Related]
13. Five years follow-up of invasive prolactinomas with special reference to the control of cavernous sinus invasion.
Wu ZB; Su ZP; Wu JS; Zheng WM; Zhuge QC; Zhong M
Pituitary; 2008; 11(1):63-70. PubMed ID: 17917811
[TBL] [Abstract][Full Text] [Related]
14. An Economic Analysis of Bromocriptine Versus Trans-Sphenoidal Surgery for the Treatment of Prolactinoma.
Duan L; Yan H; Huang M; Zhang Y; Gu F
J Craniofac Surg; 2017 Jun; 28(4):1046-1051. PubMed ID: 28145933
[TBL] [Abstract][Full Text] [Related]
15. Medical treatment of prolactinomas.
Molitch ME
Endocrinol Metab Clin North Am; 1999 Mar; 28(1):143-69, vii. PubMed ID: 10207689
[TBL] [Abstract][Full Text] [Related]
16. Prolactinoma.
Serri O; Beauregard H; Somma M
Curr Ther Endocrinol Metab; 1994; 5():41-3. PubMed ID: 7704764
[No Abstract] [Full Text] [Related]
17. Clinical management and outcome of 36 invasive prolactinomas treated with dopamine agonist.
Yang MS; Hong JW; Lee SK; Lee EJ; Kim SH
J Neurooncol; 2011 Aug; 104(1):195-204. PubMed ID: 21107645
[TBL] [Abstract][Full Text] [Related]
18. Bromocriptine treatment of invasive giant prolactinomas involving the cavernous sinus: results of a long-term follow up.
Wu ZB; Yu CJ; Su ZP; Zhuge QC; Wu JS; Zheng WM
J Neurosurg; 2006 Jan; 104(1):54-61. PubMed ID: 16509147
[TBL] [Abstract][Full Text] [Related]
19. Surgical outcomes in hyporesponsive prolactinomas: analysis of patients with resistance or intolerance to dopamine agonists.
Hamilton DK; Vance ML; Boulos PT; Laws ER
Pituitary; 2005; 8(1):53-60. PubMed ID: 16411069
[TBL] [Abstract][Full Text] [Related]
20. Surgical indication after bromocriptine therapy on giant prolactinomas: effects and limitations of the medical treatment.
Saeki N; Nakamura M; Sunami K; Yamaura A
Endocr J; 1998 Aug; 45(4):529-37. PubMed ID: 9881903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
